News Story: Full Text
Sponsored By
NovoCure Trial
Please Click On The Above Banner For More Details
Braintumor Website


Peregrine Accepted for Poster Presentation of Cotara Trial Data At the Society of Nuclear Medicine (Business Wire)...~~~Phase I/II Evaluation of the Therapeutic Efficacy and Safety of 131I-chTNT-1/B for Treatment of Malignant Tumors.......~~~ Cotara is Peregrine`s Tumor Necrosis Therapy (TNT) drug.......Cotara is currently being studied in a multi-center Phase II study for brain cancer....- Apr 24 8:23 AM ET


Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)



Website: http://biz.yahoo.com/bw/010424/2223.html

Posted on: 04/24/2001

"Yahoo - Peregrine Accepted for Poster Presentation of Cotara Trial Data At the Society of Nuclear Medicine"
Yahoo! Finance Finance Home - Yahoo! - Help
Business Wire

[ Latest Headlines | Market Overview | News Alerts ]


Related Quotes
PPHM
1.38
+0.06
delayed 20 mins - disclaimer
Tuesday April 24, 8:23 am Eastern Time

Press Release

Peregrine Accepted for Poster Presentation of Cotara Trial Data At the Society of Nuclear Medicine

Poster Highlights Phase I/II Clinical Trial Data

TUSTIN, Calif.--(BUSINESS WIRE)--April 24, 2001-- Peregrine Pharmaceuticals Inc. (Nasdaq:PPHM - news) today announced that data from its Phase I/II Mexico City Cotara(TM) Trial has been accepted for poster presentation at the 48th Annual Meeting of the Society of Nuclear Medicine.

The meeting will be held at the Metro Toronto Convention Centre in Toronto, Canada on June 23-27.

Dr. Gabriela Cesarman of the National Institute for Medical Sciences and Nutrition, Mexico City, Mexico served as principal investigator of the trial. She will be present to discuss the results of her study titled, "Phase I/II Evaluation of the Therapeutic Efficacy and Safety of 131I-chTNT-1/B for Treatment of Malignant Tumors."

"We have gained invaluable experience with Cotara from the successful Mexico City Trial," said Dr. Terrence Chew, Peregrine's Vice President of Clinical and Regulatory Affairs. "We have used data from this study to design our current trials and file Investigational New Drug applications in the U.S. This data also will assist us in the design of future trials."

"We are pleased that Dr. Cesarman has published her experiences with Cotara and will present the data at the Society of Nuclear Medicine Annual Meeting," said Edward Legere, Peregrine's President and CEO. "Peregrine encourages all of the researchers involved in its clinical studies to publish data and present at peer review conferences."

Cotara is Peregrine's Tumor Necrosis Therapy (TNT) drug. It is a radiolabeled monoclonal antibody that binds to the necrotic core of tumors and uses beta-radiation to kill the tumors from the inside out. Unlike traditional treatments such as chemotherapy, pre-clinical studies have shown TNT grows more effective with successive use as the region of necrosis grows in size. Since necrotic tissue is common to all tumors, TNT may have broad application across all tumor types.

Cotara is currently being studied in a multi-center Phase II study for brain cancer. Peregrine expects to begin a Phase III study for brain cancer later this year. Cotara is also in Phase I studies for colorectal, pancreatic, biliary and sarcoma cancers at Stanford University and a Phase I liver cancer study at the Mayo Clinic. Peregrine plans to open additional Cotara Phase I studies in the future.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development, commercialization and licensing of unique technologies for the treatment of cancer, primarily based on its "collateral targeting technologies." These technologies therapeutically target cell structures and cell types, rather than surface cancer cells, as a means to attack solid tumors, without causing damage to surrounding healthy tissue. The Company has three collateral targeting technologies: Tumor Necrosis Therapy (TNT), Vasopermeation Enhancement Agents (VEA), and Vascular Targeting Agents (VTA). The Company also has a direct tumor-targeting agent called Oncolym® for the treatment of advanced non-Hodgkin's B-cell Lymphoma. Oncolym has been licensed to Schering AG, Germany, which is now responsible for all existing and future Oncolym clinical trial programs as well as marketing.

Safe Harbor Statement: This release may contain certain forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ from the Company's expectations as a result of risk factors discussed in Peregrine's reports on file with the U.S. Securities and Exchange Commission, including, but not limited to, the Company's report on Form 10K for the year ended April 30, 2000 and Form 10Q for the quarter ended January 31, 2001.


Contact:
     DeMonte Associates, New York
     Cynthia DeMonte, 800/987-8256 or 212/420-0088

Email this story - Most-emailed articles - Most-viewed articles


More Quotes and News:Peregrine Pharmaceuticals Inc (NasdaqSC:PPHM - news)
Related News Categories: biotech, health care, medical/pharmaceutical

Help


Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Questions or Comments?
"


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740